Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NOS2 | P35228 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NOS3 | P29474 | 2/20 | 0.51 |
| ▸ | NOS1 | P29475 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487944 | 0.85 | THRB (0.68) | THRBATML3MBTL1GAAKMT2A | |
| SCHEMBL6264941 | 0.84 | L3MBTL1 (0.62) | THRBATML3MBTL1GAAKMT2A | |
| SCHEMBL20960390 | 0.84 | THRB (0.62) | THRBATML3MBTL1GAAKMT2A | |
| SCHEMBL8367374 | 0.84 | THRB (0.66) | THRBATML3MBTL1GAAKMT2A | |
| SCHEMBL14476235 | 0.84 | THRB (0.66) | THRBATML3MBTL1GAAKMT2A | |
| SCHEMBL1128414 | 0.84 | THRB (0.66) | THRBATML3MBTL1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL17074783 | 0.82 | THRB (0.64) | THRBATML3MBTL1GAAKMT2A | |
| SCHEMBL6969097 | 0.82 | L3MBTL1 (0.64) | THRBATML3MBTL1GAAKMT2A | |
| SCHEMBL9774617 | 0.82 | THRB (0.69) | THRBATML3MBTL1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL1128412 | 0.82 | THRB (0.64) | THRBATML3MBTL1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-111643496-A | Methods of using MEK inhibitors | 埃克塞利希斯股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS, INC. | 2020-01-30 | — | — | US | disclosed |
| CN-110668988-A | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| CN-104892582-B | Azetidine as the mek inhibitor for treating proliferative disease | 埃克塞利希斯股份有限公司 | 2019-09-27 | — | — | CN | disclosed |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2019-05-16 | — | — | US | disclosed |
| CN-109053523-A | Azetidine as the mek inhibitor for treating proliferative disease | 埃克塞利希斯股份有限公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-1934174-B1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS INC (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7915250-B2 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | EXELIXIS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100249096-A1 | anticarcinogenic agent; 1-({4-[(2-fluoro-4-iodophenyl)amino]-3-thienyl}carbonyl)azetidin-3-amine | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7803839-B2 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-2101759-A1 | METHODS OF USING MEK INHIBITORS | Exelixis, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283383-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | THRB 1617/4885ATM 539/4885L3MBTL1 3802/4885 |
| US-20100249096-A1 | anticarcinogenic agent; 1-({4-[(2-fluoro-4-iodophenyl)amino]-3-thienyl}carbonyl)azetidin-3-amine | NRAS, BRAF, KRAS | THRB 1836/4885ATM 565/4885L3MBTL1 4236/4885 |
| US-20090156576-A1 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | NRAS, BRAF, KRAS | THRB 2779/4885ATM 948/4885L3MBTL1 3971/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | THRB 3144/4885ATM 973/4885L3MBTL1 3691/4885 |
| US-20190144382-A1 | MEK Inhibitors and Methods of Their Use | BRAF, NRAS, MAP3K20 | THRB 1617/4885ATM 539/4885L3MBTL1 3802/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | THRB 1617/4885ATM 539/4885L3MBTL1 3802/4885 |
| US-20200031770-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, MAP3K20 | THRB 1617/4885ATM 539/4885L3MBTL1 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.